SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts
- Thirteen Renowned Medical Experts Slated to Attend First National Symposium -
CORTLAND, N.Y., June 25 /PRNewswire/ -- The first national symposium designed to explore the health impacts of energy drinks will be held next week in New York City when thirteen top experts gather to present rese...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation
COPENHAGEN, June 9 /PRNewswire/ -- A new analysis
demonstrated that a greater proportion of patients with moderately to severely active rh...
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis
entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
NATICK, Mass. and BARCELONA, Spain, May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis
of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that percutaneous coronary ...
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy Analysis
indicates that one life is now saved for every six patients who receive an ICD
NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that an analysis
of long-term data from the MADIT II clinical study demonstrates that the life-s...
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart att...
New Imaging Analysis Predicts Brain Tumor Survival
U-M researchers develop 'parametric response map' to analyze changes in a tumor's blood flow, volume
ANN ARBOR, Mich., April 20 /PRNewswire-USNewswire/ -- As early as one week after beginning treatment for brain tumors, a new imaging analysis
method was able to predict which patients would li...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
NATICK, Mass. and ORLANDO, Fla., March 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis
of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that while the overall cost ...
CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
'Positive Deviance' Efforts Turn the Tide on Antibiotic-Resistant Infections
PRINCETON, N.J., March 23 /PRNewswire-USNewswire/ -- The Robert Wood Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today announce results from an analysis
of a multifaceted methicillin-resistant Staphy...
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana
Biosciences (Nasdaq: HNAB ) today announced that an Independent Data Monitoring
Committee (IDMC) has completed a planned, pre-specified safety review of interim
data from the ongoing pivotal rALLy clinical trial of Marqibo(R...
New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy
American Heart Association rapid access journal report:
A new analysis
estimates more than 11 million older Americans could be newly eligible for statin therapy if findings from the JUPITER trial are adopted into guidelines.
That could take the...
Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
PLEASANTON, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Thoratec Corporation
(Nasdaq: THOR ), a world leader in device-based mechanical circulatory support
therapies to save, support and restore failing hearts, said today that a
pre-specified interim analysis
of data from its HeartMate II Destinati...
New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity
While LDL control has improved, there is an urgent need for more
comprehensive lipid control to protect against heart disease
NEW ORLEANS, Nov. 9 /PRNewswire/ -- A new 30-year analysis
National Health and Nutrition Examination Survey (NHANES) database
conducted by the National Lipid A...
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq:
DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM)
(lapuleucel-T), an investigational active cellular immunotherapy, at the
Chemotherapy Foundation Symposium in New York City. The presentation, whi...
Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Additional Data Presentation Shows Encouraging 12-Month Outcomes from
Single- Center Study Involving Patients with Predominantly Complex Lesions
WASHINGTON, Oct. 14 /PRNewswire/ -- OrbusNeich today announced that an
of 12-month follow-up data from the global e-HEALING
Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
TAK-390MR Data Presented at the American College of Gastroenterology Annual Meeting
ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Combined results from two Phase 3
studies presented at the American College of Gastroenterology Annual
Scientific Meeting (ACG) in Orlando, Fla...
Fralex provides update on timing of interim analysis results
TORONTO, Sept. 25 /PRNewswire-FirstCall/ - Fralex Therapeutics Inc.
(TSX:FXI) ("Fralex" or the "Company"), a medical technology company
developing a non-invasive neuromodulation device, today provided an update
on receiving results of the interim analysis
for the RELIEF pivotal study.
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
showed that Multaq(R) (dronedarone) decreased the risk of
stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately treated by antithrombotic therapy
BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
PARIS, September 3 /PRNewswire-FirstCall/ --
- This Analysis
Showed That Multaq(R) (Dronedarone) Decreased the Risk
of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter
Already Adequately Treated by Antithrombotic Therapy
The results of a post-hoc analysis
of the data fr...
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that enrollment
into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for
the treatment of acute ischemic stroke has reached the level of patients
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
SEATTLE, July 23 /PRNewswire-FirstCall/ -- Dendreon Corporation
(Nasdaq: DNDN ) today announced that it expects the Independent Data
Monitoring Committee (IDMC) to review in October 2008 the interim analysis
of overall survival relating to the Company's Phase 3 IMPACT (IMmunotherapy
New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
MARIETTA, Ga., June 17 /PRNewswire/ -- Solvay Pharmaceuticals, Inc.
announced today that a new analysis
of pivotal study data conducted by the
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
showed that initial treatment response of hypogonadal men with AndroGel(R)
GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
ST. JOSEPH, Mich., June 17 /PRNewswire/ -- GeneGo, Inc., a leading
provider of databases, software and services in systems biology, announced
today that they were awarded a Phase I SBIR from National Cancer Institute
(NCI) for the development of a platform for functional data analysis
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ --
NicOx S.A. (Euronext Paris: COX) today announced an additional analysis
of the blood pressure data from the 301 phase 3 study, showing a
statistically significant difference between naproxcinod and naproxen in
terms of the mean chan...
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- New data from a
of patients with mixed dyslip...
New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
A Separate Retrospective Analysis
of US Employer Claims Suggests a Benefit
of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with Inflammatory Bowel Disease
SAN DIEGO, May 20 /PRNewswire/ -- Data from a new analysis
Active Ulcerative Colitis Tri...
New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
announced findings from a new data analysis
that was conducted to examine
treatment differences with DAYTRANA(TM) (methylphenidate transdermal
system) between ...
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Second Phase Opens With Higher Dose Regimens
SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies
Corporation announced today that Interim Analysis
of an on-going Phase I/II
study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor
activity with no majo...
AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
RESEARCH TRIANGLE PARK, N.C., April 17 /PRNewswire/ -- AlphaVax, Inc.
announced today an initial analysis
of data from a Phase I clinical trial
of a cytomegalovirus (CMV) vaccine that is based on its platform alphavirus
replicon vector technology.
The trial is a placebo-controlled, randomize...
Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients
Data from 150 lung transplant patients demonstrates potential to improve management of risk for infection
BOSTON, April 10 /PRNewswire/ -- A prospective analysis
collected from 170 patients receiving lung transplantation at the
University of Pittsburgh Medical Center...
Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- Favrille, Inc.
(Nasdaq: FVRL ), a biopharmaceutical company developing patient-specific,
active immunotherapies for the treatment of cancer, announced today that it
has reached the data cutoff date for the Company's Phase 3 registration
Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
REDWOOD SHORES, Calif., April 8, 2008 /PRNewswire/ -- Navigenics, a
genetic health services company, today announced a new study of genetic
predisposition analysis. The Mayo Clinic study will examine how patients
understand and use information provided by a Navigenics genetic risk
TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ --
Boston Scientific Corporation (NYSE: BSX ) today announced results from a
of patients from its TAXUS IV and TAXUS V randomized
clinical trials. The analysis
compared the safety and efficacy of the
TRITON-TIMI 38 Stent Analysis Favors Prasugrel
Regardless of stent timing and type, prasugrel bests clopidogrel
CHICAGO, March 29 /PRNewswire/ -- Prasugrel has been shown to block
platelet activity in patients with acute coronary syndromes (ACS) more
effectively than clopidogrel, and to cut by more than half the risk of
thrombosis, or ...
NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
ANN ARBOR, Mich., March 20 /PRNewswire/ -- NanoBio Corporation
announced today that it has seen promising results from an interim analysis
of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail
fungus). Although the details remain confidential, the results clearly
Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
American Society of Breast Surgeons Study Represents Largest Patient Population to Date
BEDFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Hologic, Inc.
(Nasdaq: HOLX ) a diversified medical technologies company specializing in
imaging systems, diagnostics, and inter...
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Conference Call Scheduled for 10:00 a.m. ET Today
SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data
Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3
clinical trials of...
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH ) today announced that an independent Data
Monitoring Committee (DMC) has completed the pre-specified 65-patient
safety review of data from the Company's pivotal Phase 2 PROPEL trial of
Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq:
GXDX), a provider of personalized diagnostic services, announced today at
the ASH Meeting in Atlanta, Georgia, that it will launch testing for the
MPL W515 L/K mutation. This new test further expands the Genoptix service
New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
Dr. Jim Kim joins teleconference to release report with ITPC. Kim says
foundations laid by AIDS response are "the best chance we've ever had to
build comprehensive health systems in the poorest settings."
NEW YORK AND CAPE TOWN, South Africa, Nov.27 /PRNewswire-USNewswire/ --